A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : Scl GVHD / sclerodermatous graft-vs-host disease

[Related PubMed/MEDLINE]
Total Number of Papers: 16
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   Scl GVHD  (>> Co-occurring Abbreviation)
Long Form:   sclerodermatous graft-vs-host disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 The Gut Bacteria Dysbiosis Contributes to Chronic Graft-Versus-Host Disease Associated With a Treg/Th1 Ratio Imbalance. IFN-gamma, IL
2020 CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model. cGVHD, hMSC, hMSCs
2020 Fractional CO2 laser for the treatment of sclerodermatous cGVHD. ---
2017 A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice. alpha-SMA, IL, SSc, TGF, TNF
2017 Mesenchymal Stem Cells (MSCs) AttenuateCutaneous Sclerodermatous Graft-Versus-Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration in a Mouse Model. GVHD, MSCs
2017 Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis. SSc
2016 IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. dLNs, LECs, S1P, SSc
2014 Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages. LXRs, Tsk-1
2013 What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis? IFN, SSc
10  2012 Egr-ly awaiting a "personalized medicine" approach to treat scleroderma. Egr, IL-13
11  2012 Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. ---
12  2008 Animal models in systemic sclerosis. SSc
13  2006 Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. mRNAs, VEGF
14  2003 Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. LAP, TGF-beta1
15  2002 Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. ---
16  1999 Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. ---